Table 2

Proposed EORTC 1999 criteria for clinical and subclinical response assessment by PET-CT
Response Definition
Progressive metabolic disease An increase in 18FDG tumor SUV of greater than 25% within the tumor region defined on the baseline scan, visible increase in the extent of 18FDG tumor uptake (>20% in the longest dimension) or the appearance of new 18FDG uptake in metastatic lesions
Stable metabolic disease An increase in tumor 18FDG SUV of less than 25% or a decrease of less than 15% and no visible increase in extent of 18FDG tumor uptake (>20% in the longest dimension)
Partial metabolic response A reduction of a minimum of 15–25% in tumor 18FDG SUV after one cycle of chemotherapy, and greater than 25% after more than one treatment cycle
Complete metabolic response Complete resolution of 18FDG uptake within the tumor volume so that it was indistinguishable from surrounding normal tissue

Topkan et al.

Topkan et al. BMC Cancer 2012 12:502   doi:10.1186/1471-2407-12-502

Open Data